• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Characterizing the antigenic evolution of pandemic influenza A (H1N1) pdm09 from 2009 to 2023

tetano

Editor, Senior Moderator
J Med Virol


. 2024 May;96(5):e29657.
doi: 10.1002/jmv.29657. Characterizing the antigenic evolution of pandemic influenza A (H1N1) pdm09 from 2009 to 2023

Peiwen Cheng[SUP] 1 2 [/SUP], Ke Zhai[SUP] 1 2 [/SUP], Wenjie Han[SUP] 1 2 [/SUP], Jinfeng Zeng[SUP] 1 2 [/SUP], Zekai Qiu[SUP] 1 2 [/SUP], Yilin Chen[SUP] 1 2 [/SUP], Kang Tang[SUP] 3 [/SUP], Jing Tang[SUP] 1 2 [/SUP], Haoyu Long[SUP] 1 2 [/SUP], Taijiao Jiang[SUP] 4 5 6 [/SUP], Xiangjun Du[SUP] 1 2 7 8 [/SUP]



Affiliations
Abstract

The H1N1pdm09 virus has been a persistent threat to public health since the 2009 pandemic. Particularly, since the relaxation of COVID-19 pandemic mitigation measures, the influenza virus and SARS-CoV-2 have been concurrently prevalent worldwide. To determine the antigenic evolution pattern of H1N1pdm09 and develop preventive countermeasures, we collected influenza sequence data and immunological data to establish a new antigenic evolution analysis framework. A machine learning model (XGBoost, accuracy = 0.86, area under the receiver operating characteristic curve = 0.89) was constructed using epitopes, physicochemical properties, receptor binding sites, and glycosylation sites as features to predict the antigenic similarity relationships between influenza strains. An antigenic correlation network was constructed, and the Markov clustering algorithm was used to identify antigenic clusters. Subsequently, the antigenic evolution pattern of H1N1pdm09 was analyzed at the global and regional scales across three continents. We found that H1N1pdm09 evolved into around five antigenic clusters between 2009 and 2023 and that their antigenic evolution trajectories were characterized by cocirculation of multiple clusters, low-level persistence of former dominant clusters, and local heterogeneity of cluster circulations. Furthermore, compared with the seasonal H1N1 virus, the potential cluster-transition determining sites of H1N1pdm09 were restricted to epitopes Sa and Sb. This study demonstrated the effectiveness of machine learning methods for characterizing antigenic evolution of viruses, developed a specific model to rapidly identify H1N1pdm09 antigenic variants, and elucidated their evolutionary patterns. Our findings may provide valuable support for the implementation of effective surveillance strategies and targeted prevention efforts to mitigate the impact of H1N1pdm09.

Keywords: H1N1pdm09; XGBoost; antigenic correlation network; evolutionary patterns; potential cluster‐transition determining sites.

 
Back
Top